Glaucoma Global Market Report 2025: A Comprehensive Analysis Of Increasing Market Size, And Forecasts.

February 25, 2025 06:46 AM GMT | By EIN Presswire
 Glaucoma Global Market Report 2025: A Comprehensive Analysis Of Increasing Market Size, And Forecasts.
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, February 25, 2025 /EINPresswire.com/ -- Did You Know That The Glaucoma Market Size Has Shown Remarkable Growth In Recent Times?

The glaucoma market size is set to expand from $7.76 billion in 2024 to $8.22 billion in 2025. This increase, reflective of a compound annual growth rate CAGR of 5.9%, can be attributed to significant factors, such as increasing awareness of eye health, increasing healthcare spending, widespread adoption of telemedicine for eye care, expanding healthcare infrastructure, and an increase in government healthcare initiatives.

In the coming years, the glaucoma market size is anticipated to witness continued robust growth. By the year 2029, it is predicted to reach $10.20 billion, with a compound annual growth rate CAGR of 5.5%. This growth can be linked to various factors, including an aging population, rising prevalence of glaucoma, a growing demand for minimally invasive surgeries, and a surge in the prevalence of diabetes and hypertension.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20820&type=smp

What Drives The Glaucoma Market Growth?

One cannot overlook the increasing prevalence of chronic eye conditions, which are expected to propel the growth of the glaucoma market going forward. Chronic eye conditions, rising due to aging populations, increased screen time, lifestyle factors, and a higher prevalence of conditions like diabetes and hypertension, often result in persistent vision impairment or discomfort and require ongoing management or treatment. To mitigate the risk of further optic nerve damage, intraocular pressure needs to be lowered with glaucoma treatment to preserve vision, as untreated glaucoma can lead to irreversible blindness.

For instance, take into account data from December 2024. According to the National Health Service NHS, a UK-based publicly funded healthcare system, over 2 million people in the UK were living with sight loss in 2024. Moreover, the number of people living with sight loss is projected to increase by 27%, reaching approximately 2.8 million by 2035. Clearly, the rising prevalence of chronic eye conditions is driving the glaucoma market.

Order Your Report Now For A Swift Delivery: https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report

Who Are The Key Players In The Glaucoma Market?

Major companies hold key roles in the glaucoma market, including Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Viva BioInnovator, Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Renova Life Sciences Private Limited, Qlaris Bio Inc., PolyActiva Pty Ltd., Nidek Co. Ltd., and Haag-Streit AG.

What Are The Emerging Trends In The Glaucoma Market?

Innovation remains a strong trend within the industry, with leading companies developing therapies such as Rho-kinase ROCK inhibitors, which reduce intraocular pressure through both enhanced outflow of aqueous humor and the relaxation of trabecular meshwork cells. This dual mechanism of operation makes them highly effective in treating glaucoma.

How Is The Glaucoma Market Segmented?

1 By Disease Type: Open Angle Glaucoma, Angle Closure Glaucoma, Other Disease Types
2 By Diagnosis: Tonometry, Ophthalmoscopy, Perimetry, Gonioscopy
3 By Drug Class: Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Other Drug Classes
4 By Administration: Oral, Injections, Intravitreal, Other Administrations
5 By End-User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers

Each segment is further divided into several other subsegments, providing a detailed scope of the market.
What Is The Regional Analysis Of Glaucoma Market?

From a regional viewpoint, North America was the largest region in the glaucoma market in 2024. However, Asia-Pacific holds promise as the potential fastest-growing region in the forecast period. Other regions covered in the glaucoma market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse For More Similar Reports-

Antiglaucoma Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report
Glaucoma Surgery Devices Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/glaucoma-surgery-devices-global-market-report
Dry Eye Medication Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/dry-eye-medication-global-market-report

About The Business Research Company.

Learn More About The Business Research Company. With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us: [email protected]

Stay connected:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
Facebook
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next